Tempus AI Targets 100K Whole-Genome Dataset to Power AI Drug Discovery
TEM sits 45% above its 52-week low of $40.77.
Summary
Tempus AI announced a multi-year initiative to build a de-identified multimodal whole-genome sequencing dataset of 100,000 genomes linked to longitudinal clinical outcomes, with plans to expand to one million genomes. The dataset will be integrated into Tempus Lens, its existing AI research environment, and is available now through an Early Adopter Program with general availability targeted for mid-2027. This builds on Tempus' existing oncology database and AI foundation models, extending its data moat from targeted panels to whole-genome sequencing. The move strengthens Tempus' position in AI-driven drug development and precision medicine, though revenue impact is not yet quantified.
At the time of this announcement, TEM was trading at $59.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6B. The 52-week trading range was $40.77 to $104.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.